`Filed: August 20, 2015
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`COALITION FOR AFFORDABLE DRUGS VI LLC
`Petitioner,
`
`v.
`
`CELGENE CORPORATION
`Patent Owner
`
`________________
`
`Case IPR2015-01102
`Patent 6,315,720
`________________
`
`PATENT OWNER REPLY IN SUPPORT OF ITS MOTION FOR
`SANCTIONS PURSUANT TO 35 U.S.C. § 316(a)(6) AND 37 C.F.R. § 42.12
`
`
`
`
`
`
`
`
`
`04841-00006/7124493.1
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`TABLE OF CONTENTS
`
`IPR2015-01102
`Patent 6,315,720
`
`Page
`
`I.
`
`CFAD DOES NOT DENY PATENT OWNER’S FACTS ............................ 1
`
`II. ARGUMENT ................................................................................................... 2
`
`The Petition is improper under the
`AIA and does not serve the public interest ...................................................... 2
`
`CFAD is abusing and improperly using the IPR process ................................ 3
`
`Noerr-Pennington does not shield CFAD from sanctions .............................. 4
`
`The Board can dismiss the Petition prior to institution ................................... 5
`
`III. CONCLUSION ................................................................................................ 5
`
`04841-00006/7124493.1
`
`- i -
`
`
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`IPR2015-01102
`Patent 6,315,720
`
`CFAD’s focus on standing and the propriety of short selling is an attempt to
`
`divert attention from the real issue: whether the manner in which CFAD uses IPRs
`
`should be permitted. The answer is “no.” The use of IPRs to execute an
`
`investment strategy—shorting stocks and then filing IPRs to drive down stock
`
`prices—is improper, and an abuse of the IPR process that turns the AIA on its
`
`head. This is true regardless of the merits of any petition. Here, Noerr-Pennington
`
`does not protect CFAD’s actions. And despite CFAD’s protests, the regulations
`
`expressly allow for “dismissal of the petition”; institution of trial is not necessary.
`
`I.
`
`CFAD DOES NOT DENY PATENT OWNER’S FACTS1
`
`First, CFAD does not deny that the RPI demanded payment in exchange for
`
`not filing IPRs in 2014. Instead, CFAD argues that PO presented no evidence, but
`
`ignores that Ex. 2033 explains Spangenberg’s negotiation tactics. And at least one
`
`court has recognized that the “or else! oozes” from statements similar to
`
`Spangenberg’s 2014 email to Celgene. POM at 2-4 & Ex. 2034. Further, CFAD’s
`
`counsel admitted during the Board call that authorized this motion that payment
`
`was discussed. The discussions may be confidential, but at the Board’s request,
`
`Celgene can supply evidence of the RPI’s substantial demand.
`
`Second, CFAD does not deny its use of IPRs to execute its investment
`
`strategy. Instead, it argues that “short selling is common, legal and regulated.”
`
`
`
`
`1 PO responds to CFAD’s “material facts” in Appendix A. 37 CFR § 42.24(c).
`
`04841-00006/7124493.1
`
`- 1 -
`
`
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`IPR2015-01102
`Patent 6,315,720
`
`Opp. at 6. Whether short selling is generally proper is irrelevant. CFAD offers no
`
`evidence that taking short positions on publicly-traded companies, and then using
`
`government petitions (IPRs) to drive down the companies’ stock prices, is proper
`
`or contemplated by the AIA. PO presented evidence that the PTO “never thought”
`
`that IPRs would be used “to move stock or as an investment vehicle.” POM at 9.2
`
`Third, CFAD does not deny that it: (1) formed for-profit shell companies
`
`whose “primary purpose” is to short stocks; (2) has no competitive interest in the
`
`challenged patents; and (3) owes its investors a fiduciary duty that puts its
`
`investment strategy above any alleged altruistic mission. POM at 5-7.
`
`II. ARGUMENT
`
`The Petition is improper under the AIA and does not serve the public
`
`interest. CFAD’s arguments to the contrary lack merit. First, CFAD incorrectly
`
`argues that the AIA’s standing provision is fatal to POM. Opp. at 7. POM is not
`
`challenging who CFAD is, but how it is using IPR proceedings. While anyone can
`
`file a petition, the regulations expressly permit dismissal of a petition that is used
`
`for an improper purpose or if it is an abuse of process. 37 CFR § 42.12.
`
`Second, CFAD complains about PO’s citations to the 2007 PRA legislative
`
`history (Opp. at 7-8), but ignores that all of PO’s arguments are supported by the
`
`
`
`
`2 Contrary to CFAD’s incorrect assertion, newspapers are “evidence that is self-
`
`authenticating.” See FRE 902(6); 37 CFR § 42.62.
`
`04841-00006/7124493.1
`
`- 2 -
`
`
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`IPR2015-01102
`Patent 6,315,720
`
`AIA’s 2011 legislative history (POM at 7-8). Congress clearly intended to stop
`
`non-practicing entities (“NPE”), like CFAD, from using abusive litigation tactics
`
`for personal financial gain. Id. Congress did not intend to allow those same NPE
`
`to turn around and use abusive IPR tactics for personal financial gain. Id.
`
`Third, CFAD’s caselaw does not support its position. As CFAD
`
`emphasizes, the Supreme Court encouraged “interested persons,” such as
`
`“licensees,” to challenge patents. Opp. at 9, 1. CFAD has not presented any
`
`evidence that it is an “interested person.” It cannot. It does not seek to market a
`
`competing generic product, and it has not licensed Celgene’s patents. Also, its
`
`IPRs (even if successful) will not result in generic competition, at least because, as
`
`CFAD admits, it has not challenged all of Celgene’s Orange Book patents. Opp. at
`
`4. In any event, FDA, not CFAD, controls access to generics, and FDA has not
`
`even tentatively approved any generic version of Thalomid®, Revlimid®, or
`
`Pomalyst®. Further, there are several interested parties that can challenge
`
`Celgene’s patents under the AIA. Their petitions would be proper. CFAD’s is not.
`
`CFAD is abusing and improperly using the IPR process. CFAD does not
`
`challenge that its actions are an abuse of process under Neumann. Rather, it argues
`
`that “Neumann has been abrogated, criticized, and distinguished.” Opp. at 10.
`
`This is false. Neumann remains good law. State and/or federal district courts
`
`cannot “abrogate” a circuit court decision, and later decisions from the same court
`
`04841-00006/7124493.1
`
`- 3 -
`
`
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`IPR2015-01102
`Patent 6,315,720
`
`do not reverse earlier ones unless they do so explicitly; that has not occurred.
`
`Regardless, CFAD’s actions are an abuse of process even under its cited caselaw,
`
`which focuses on improper motive (which is admitted) and some other act that is
`
`not a “regular” part of the proceedings. Here, CFAD is admittedly using IPRs to
`
`affect stock prices to cash in on “short” positions. This is “some end which is
`
`without the regular purview of [IPRs],” and an “act in the use of process other
`
`than such as would be proper in the regular prosecution of [IPRs].” Opp. at 10-12.
`
`Even if CFAD’s short positions are not illegal, its use of IPRs to execute its
`
`investment strategy is not within the regular purview of IPRs.3
`
`Noerr-Pennington (“NP”) does not shield CFAD from sanctions. NP is
`
`not a defense to “common litigant sanctions imposed by courts themselves.”
`
`BE&K Const. v. NLRB, 536 U.S. 516, 537 (2002). This logically extends to the
`
`Board’s discretion to issue sanctions here. NP also requires a “grievance,” which
`
`CFAD does not have; it cannot be injured by the ’720 patent. Even assuming that
`
`NP applies—it does not—CFAD mischaracterizes the standard for proving that its
`
`petitions are a “sham.” Opp. at 12-14 (alleging that PO must prove objective and
`
`subjective baselessness). Instead, when the petitioner “is accused of bringing a
`
`
`3 CFAD also argues that dismissal is improper because filing the Petition does not
`
`
`
`constitute process being issued, but ignores that even threats to file petitions can
`
`support abuse of process. See 5 FCC Rcd. 3911, 3912 (1990).
`
`04841-00006/7124493.1
`
`- 4 -
`
`
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`IPR2015-01102
`Patent 6,315,720
`
`whole series of legal proceedings”—as is the case here—“the test is . . . [w]ere the
`
`legal filings made, not out of a genuine interest in redressing grievances, but as a
`
`part of a pattern or practice of successive filings undertaken essentially for
`
`purposes of harassment?” Primetime 24 v. Nat’l Broad Co., 219 F.3d 92, 101 (2d
`
`Cir. 2000). Here, the answer is “yes.” CFAD’s “series of legal proceedings” is
`
`“harassment” that is, among other things, frightening off investors. This is an
`
`abuse of process under Neumann. POM at 11-13. Further, Abbott and Baker do
`
`not support CFAD’s position. Opp. at 13-14. Both rejected tort abuse-of-process
`
`claims because, as Abbott noted, “PTO procedures themselves provide a remedy.”
`
`952 F.2d at 1357; Baker, 478 F. Supp. at 860 (PTO should “decide [issues] without
`
`interference from this court”). Here, the PTO’s remedy is sanctions.
`
`The Board can dismiss the Petition prior to institution. CFAD is wrong
`
`to suggest that the statute’s use of the word “proceeding” requires the Board to
`
`wait until after institution. See, e.g., CBM2014-00142, Paper 10 (dismissing
`
`petition under § 42.12(b)(8) before institution for failing to comply with “[c]onduct
`
`of the proceeding”). In any event, abuse of process and improper use of the
`
`proceeding are separate sanctionable actions under 37 CFR § 42.12(a), and no
`
`“proceeding” is required for “abuse of process.”
`
`III. CONCLUSION
`
`For these reasons and those in POM, the Petition should be dismissed.
`
`04841-00006/7124493.1
`
`- 5 -
`
`
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`IPR2015-01102
`Patent 6,315,720
`
`
`
`Date: August 20, 2015
`
` Respectfully submitted,
`
`By: /F. Dominic Cerrito (Reg. No. 38,100)/
`F. Dominic Cerrito (Reg. No. 38,100)
`QUINN EMANUEL URQUHART &
`SULLIVAN, LLP
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`Tel: (212) 849-7000
`Fax: (212) 849-7100
`nickcerrito@quinnemanuel.com
`
`Anthony M. Insogna (Reg. No. 35,203)
`JONES DAY
`12265 El Camino Real
`Suite 200
`San Diego, CA 92130
`Tel: (858) 314-1200
`Fax: (858) 314-1150
`aminsogna@jonesday.com
`
`Attorneys for Celgene Corporation
`
`04841-00006/7124493.1
`
`- 1 -
`
`
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`IPR2015-01102
`Patent 6,315,720
`
`APPENDIX A
`
`Celgene (Patent Owner or “PO”) listed the challenged ’501 and ’720 patents in the
`
`FDA’s Orange Book for not just one—but three—of its branded drugs:
`
`Thalomid®, Revlimid®, and Pomalyst®. (Exs. 1034, 1035.)
`
`PO admits that it submitted the ’501 and ’720 patents to the FDA for listing in
`
`the “Orange Book” in connection with the New Drug Applications for
`
`Thalomid®, Revlimid®, and Pomalyst® and, except as so admitted, denies
`
`CFAD’s allegations.
`
`PO has asserted both patents to prevent generic entry of Thalomid, and to prevent
`
`generic entry of Revlimid.
`
`PO admits that it asserted the ’501 and ’720 patents against filers of
`
`Abbreviated New Drug Applications (“ANDA”) that infringed those patents
`
`by filing certifications with the FDA pursuant to 21 USC
`
`§ 355(j)(2)(A)(vii)(IV) against those patents and, except as so admitted, denies
`
`CFAD’s allegations.
`
`PO asserted both challenged patents (and others) in lawsuits filed against three
`
`different generics to delay and prevent FDA approval of their ANDAs until the
`
`patents expire.
`
`04841-00006/7124493.1
`
`- 1 -
`
`
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`IPR2015-01102
`Patent 6,315,720
`
`PO admits that it asserted patents against ANDA filers that infringed those
`
`patents by filing certifications with the FDA pursuant to 21 USC
`
`§ 355(j)(2)(A)(vii)(IV) against those patents and, except as so admitted, denies
`
`CFAD’s allegations.
`
`PO asserted the two challenged patents against Barr’s Thalomid ANDA in January
`
`2007 (Ex. 1039), against Natco’s Revlimid ANDA in October 2010 (Ex. 1040),
`
`and against Lannett’s Revlimid ANDA in January 2015 (Ex. 1041).
`
`PO admits that it asserted the ’501 and ’720 patents against Barr in January
`
`2007, against Natco in October 2010, against Lannett in January 2015, and,
`
`except as so admitted, denies CFAD’s allegations. In particular, no patents
`
`were asserted against any “ANDA” and, to PO’s knowledge, Lannett has
`
`never filed a Revlimid ANDA.
`
`PO settled with Barr in May 2010 (Ex. 1042), and was subsequently sued by a
`
`union accusing PO of asserting the challenged patents against generics in “sham”
`
`litigation (Ex. 1043 at 32, 49-55).
`
`PO denies that it settled with Barr. Barr voluntarily and unilaterally
`
`withdrew its ANDA (see Celgene Corp. v. Barr Labs., Inc., No. 07-286 at D.I.
`
`157 (D.N.J. May 13, 2010)), after which the case against Barr was dismissed
`
`and Barr’s counterclaims were dismissed with prejudice (see Celgene Corp. v.
`
`04841-00006/7124493.1
`
`- 2 -
`
`
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`IPR2015-01102
`Patent 6,315,720
`
`Barr Labs., Inc., No. 07-286 at D.I. 160 (D.N.J. May 26, 2010)). PO admits
`
`that the International Union of Bricklayers and Allied Craft Workers Local 1
`
`Health Fund filed suit against PO and, except as so admitted, denies CFAD’s
`
`allegations.
`
`Nearly five years have elapsed since PO first asserted the challenged patents
`
`against Natco, and no decision on the merits of Natco’s invalidity challenge has
`
`issued—and is unlikely to anytime soon because PO moved to stay the litigation on
`
`the challenged patents and the stay was granted. (Ex. 1044 at 1-2, Ex. 1045.)
`
`PO admits that it first sued Natco in October 2010 and that no decision on the
`
`merits of Natco’s invalidity challenge has issued. PO admits that it filed a
`
`meritorious motion to bifurcate and stay the litigation on the ’501 and ’720
`
`patents due to facts and circumstances that are subject to a Discovery
`
`Confidentiality Order in Civil Action No. 10-5197 (D.I. 36) (D.N.J.), and
`
`Judge Arleo granted that motion. PO otherwise lacks knowledge or
`
`information sufficient to form a belief about the truth of the remainder of
`
`CFAD’s allegations.
`
`Despite PO first asserting the challenged patents nearly nine years ago—no court
`
`has ever reached a decision on the merits of the validity of either patent.
`
`04841-00006/7124493.1
`
`- 3 -
`
`
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`IPR2015-01102
`Patent 6,315,720
`
`PO admits that no court has ever reached a decision on the merits of the
`
`validity of the ’501 and ’720 patents, and, except as so admitted, denies
`
`CFAD’s allegations.
`
`In the FDA’s Orange Book, PO currently lists 16 patents for Thalomid (Ex. 1046),
`
`25 patents for Revlimid (Ex. 1047) and 18 patents for Pomalyst (Ex. 1048).
`
`PO admits that it submitted the currently listed patents to the FDA for listing
`
`in the “Orange Book” in connection with the New Drug Applications for
`
`Thalomid®, Revlimid®, and Pomalyst® and, except as so admitted, denies
`
`CFAD’s allegations.
`
`None of these Orange Book patents had ever been challenged in any Patent Office
`
`proceeding until Petitioner filed challenges in April 2015.
`
`It is unclear what CFAD is implying. To the extent CFAD is referring to
`
`IPRs, PO admits that no IPRs had been filed against any of the Orange Book
`
`patents for Thalomid®, Revlimid®, or Pomalyst® before April 2015.
`
`Celgene’s U.S. Patent No. 6,315,517, however, has been through
`
`reexamination.
`
`The Federal Trade Commission concluded more than a decade ago that, “in some
`
`ways the patent system is out of balance with competition policy” because “poor
`
`04841-00006/7124493.1
`
`- 4 -
`
`
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`IPR2015-01102
`Patent 6,315,720
`
`patent quality” (defined as patents that are “likely invalid” or contain claims that
`
`are “likely overly broad”) “may have anticompetitive effects [that] can cause
`
`unwarranted market power and can unjustifiably increase costs.” (Ex. 1049 at 5).
`
`PO admits that the quoted language appears in Ex. 1049. PO otherwise lacks
`
`knowledge or information sufficient to form a belief about the truth of the
`
`remainder of CFAD’s allegations at least because it is an opinion, and not a
`
`fact.
`
`It is an unfortunate fact that generic competition is not effective at policing brand
`
`evergreening strategies—and a further reason that CFAD’s activities should be
`
`encouraged—not sanctioned. (Ex. 1050 at 324).
`
`PO denies CFAD’s allegations.
`
`Just three months ago, the FTC stated that the “economic and regulatory context of
`
`brand-generic competition creates incentives for [those] companies to collude
`
`rather than compete, and the brand’s profits from preserving a monopoly through
`
`anti-competitive settlement can be enormous.” (Ex. 1052 at 3.)
`
`PO admits that the quoted language appears in Ex. 1052, and, except as so
`
`admitted, denies CFAD’s allegations.
`
`04841-00006/7124493.1
`
`- 5 -
`
`
`
`
`
`Patent Owner Reply Motion For Sanctions
`
`IPR2015-01102
`Patent 6,315,720
`
`Such deals “cost consumers and taxpayers billions of dollars, driving up health
`
`care costs and depriving patients of needed medications.” Id. at 1.
`
`PO admits that the quoted language appears in Ex. 1052, and, except as so
`
`admitted, denies CFAD’s allegations.
`
`The FTC characterizes agreements ending validity challenges as “‘win-win’ for the
`
`companies: brand-name prices stay high, and the brand and generic share the
`
`benefits of the brand’s monopoly profits. Consumers lose[]: they miss out on
`
`generic prices…as much as 90 percent less than brand prices.” (Ex. 1052 at 3; see
`
`also Ex. 1053 at 1 (CEPR economic impact study of proposal to exempt
`
`pharmaceutical patents from IPRs; finding “it is likely that many dubious claims
`
`end up going unchallenged,” and estimating costs arising from improperly granted
`
`patents over the next twenty years of $73–$220 billion).)
`
`PO admits that the quoted language appears in Ex. 1052 and Ex. 1053, and,
`
`except as so admitted, denies CFAD’s allegations.
`
`04841-00006/7124493.1
`
`- 6 -
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`COALITION FOR AFFORDABLE DRUGS VI LLC
`Petitioner,
`
`v.
`
`CELGENE CORPORATION
`Patent Owner
`
`________________
`
`Case IPR2015-01102
`Patent 6,315,720
`________________
`
`
`CERTIFICATE OF SERVICE
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certify that
`
`PATENT OWNER REPLY IN SUPPORT OF ITS MOTION FOR SANCTIONS
`
`PURSUANT TO 35 U.S.C. § 316(a)(6) AND 37 C.F.R. § 42.12 was served on
`
`August 20, 2015 by filing this document through the Patent Review Processing
`
`System, as well as e-mailing a copy to sarah.spires@skiermontpuckett.com,
`
`parvathi.kota@skiermontpuckett.com, and paul.skiermont@skiermontpuckett.com.
`
`Date: August 20, 2015
`
` Respectfully submitted,
`
`By: /F. Dominic Cerrito (Reg. No. 38,100)/
`F. Dominic Cerrito (Reg. No. 38,100)
`QUINN EMANUEL URQUHART &
`SULLIVAN, LLP
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`Tel: (212) 849-7000
`Fax: (212) 849-7100
`nickcerrito@quinnemanuel.com
`
`Anthony M. Insogna (Reg. No. 35,203)
`JONES DAY
`12265 El Camino Real
`Suite 200
`San Diego, CA 92130
`Tel: (858) 314-1200
`Fax: (858) 314-1150
`aminsogna@jonesday.com
`
`Attorneys for Celgene Corporation